Analysts at Canaccord Genuity downgraded Valeant Pharmaceuticals International, Inc. (VRX) from ‘Buy’ to ‘Hold’ in a research report issued to clients on Wednesday. The target price for VRX is lowered from $125 to $75. The broker said the cut is based on growing uncertainty around the multitude of investigations, as well as the company’s decreasing reliance […]
View the full post at: Notable Downgrades: Valeant (VRX), Dollar Tree (DLTR), SanDisk (SNDK), American Water Works Co. (AWK)